drugset / Trial / NCT05512208
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.
Timeline
- Start
- 2023-02-06
- Primary completion
- 2027-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avutometinib | Small molecule | 3.2 mg | Oral |
| Subject | Defactinib | Small molecule | 200 mg | Oral |